Last reviewed · How we verify
Sunscreening Agents
At a glance
| Generic name | Sunscreening Agents |
|---|---|
| Sponsor | Henry Ford Health System |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma (NA)
- Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma (PHASE2)
- Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma (NA)
- SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners (NA)
- A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation (NA)
- A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients (EARLY_PHASE1)
- The Effectiveness of Topical Silicone Application Combined With Photoprotection in the Development of Scarring Following Blepharoplasty (PHASE4)
- Influence of Sun Protection and Linear Repair of Cutaneous Surgical Defects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sunscreening Agents CI brief — competitive landscape report
- Sunscreening Agents updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI